



Structural aspects of Vitamin D endocrinology



Natacha Rochel ^{a,*}, Ferdinand Molnár ^{b,**}

^a Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Institut National de La Santé et de La Recherche Médicale (INSERM), U964/Centre National de Recherche Scientifique (CNRS), UMR7104/Université de Strasbourg, 67404 Illkirch, France

^b Institute of Biopharmacy, School of Pharmacy, Faculty of Health Science, University of Eastern Finland, Yliopistoranta 1C, Canthia 2036, 70210 Kuopio, Finland

ARTICLE INFO

Article history:

Received 22 December 2016

Received in revised form

27 February 2017

Accepted 27 February 2017

Available online 28 February 2017

Keywords:

Vitamin D₃

DBP

CYPs

VDR

HVDRR

Structure

Allostery

ABSTRACT

1 α ,25-Dihydroxyvitamin D₃ (1,25(OH)₂D₃) is the hormonally active form of vitamin D₃. Its synthesis and its metabolites, their transport and elimination as well as action on transcriptional regulation involves the harmonic cooperation of diverse proteins with vitamin D binding capacities such as vitamin D binding protein (DBP), cytochrome P450 enzymes or the nuclear vitamin receptor (VDR). The genomic mechanism of 1,25(OH)₂D₃ action involves its binding to VDR that functionally acts as a heterodimer with retinoid X receptor. The crystal structures of the most important proteins for vitamin D₃, VDR, DBP, CYP2R1 and CYP24A1, have provided identification of mechanisms of actions of these proteins and those mediating VDR-regulated transcription. This review will present the structural information on recognition of the vitamin D₃ and metabolites by CYP proteins and DBP as well as the structural basis of VDR activation by 1,25(OH)₂D₃ and metabolites. Additionally, we will describe, the implications of the VDR mutants associated with hereditary vitamin D-resistant rickets (HVDRR) that display impaired function.

© 2017 Elsevier B.V. All rights reserved.

1. Introduction

The active form of vitamin D₃, 1 α ,25-Dihydroxyvitamin D₃ (1,25(OH)₂D₃), acts as an endocrine hormone and primarily maintains calcium levels in plasma and phosphate homeostasis. In addition to endocrine hormone actions, locally produced 1,25(OH)₂D₃ displays paracrine/autocrine actions (Morris and Anderson, 2010) that are important for epidermal differentiation (Bikle *et al.*, 2004) or innate immune response (Liu *et al.*, 2006).

Vitamin D₃ can be obtained from dietary sources or is synthesized in the skin after sunlight exposure. The activation of vitamin D₃ is accomplished by sequential hydroxylations, 25-hydroxylation of vitamin D₃ leading to 25-hydroxyvitamin D₃, 25(OH)D₃, followed by the 1 α -hydroxylation (Fig. 1). The first step of 25-hydroxylation occurs in the liver (Ponchon and DeLuca, 1969), and the second one occurs both in the kidney and extra-renal sites (Fraser and Kodicek, 1970; Hewison and Adams, 2011). Several cytochrome P450 enzymes, such as CYP2R1, CYP27A1, CYP3A4, CYP2D25, are able to

hydroxylate at C-25. The second hydroxylation at C-1 α is done by CYP27B1 (Gray *et al.*, 1972).

Catabolic desactivation pathways include a carbon-24 oxidation by CYP24A1 leading to calcitroic acid production, and a 26,23-lactone pathway for converting both 25(OH)D₃ and 1,25(OH)₂D₃ to lactone products (Prosser and Jones, 2004). All of the CYPs that are involved in vitamin D hydroxylation, catalyze single or multiple hydroxylation reactions on specific carbons of the vitamin D₃ substrate using a transient heme-bound intermediate. All CYP proteins show high conservation and exhibit a common secondary structure with multiple highly conserved helices, A to L, connected by loops and β -sheet structures. Crystal structures of CYP2R1 (Strushkevich *et al.*, 2008) and CYP24A1 (Annalora *et al.*, 2010) provided insights into the vitamin D hydroxylation mechanism.

Vitamin D₃ metabolites including 1,25(OH)₂D₃ are transported by a serum vitamin D binding protein (DBP), also known as GC-globulin (Daiger *et al.*, 1975). DBP also binds saturated and unsaturated fatty acids with moderate affinity, monomeric actin and is able to depolymerize filamentous actin. The crystal structures of DBP bound to 25(OH)D₃ (Verboven *et al.*, 2002) as well as bound to actin (Otterbein *et al.*, 2002; Head *et al.*, 2002) were solved.

Most of the biological actions of 1,25(OH)₂D₃ are achieved through Vitamin D Nuclear Receptor (VDR)-mediated regulation of

* Corresponding author.

** Corresponding author.

E-mail addresses: rochel@igbmc.fr (N. Rochel), ferdinandmolnar@gmail.com (F. Molnár).




Fig. 1. (A–B) Vitamin D₃ synthesis, activation and inactivation. (C) Chemical structure and numbering of 1,25(OH)₂D₃.

Download English Version:

<https://daneshyari.com/en/article/5534047>

Download Persian Version:

<https://daneshyari.com/article/5534047>

[Daneshyari.com](https://daneshyari.com)